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In the original article, we neglected to include the funder NCTN Operations Center Grant 
U10CA180886 (current grant, as of 3/1/14) St. Baldrick’s Foundation.
The revised “Funding” should read: This work was supported by ARRA grant from the National 
Institutes of Health, by grant from the Department of Defense (AY) # W81XWH-12-1-0427, by grant 
from the NIH (AY) #5R01CA164132, the Lou Bridgeman Memorial Fund, the Alex’s Lemonade 
Stand Foundation (AY), NCTN Operations Center Grant U10CA180886 (current grant, as of 3/1/14) 
St. Baldrick’s Foundation and COG SDC grant U10CA180899.
The authors apologize for this error and state that this does not change the scientific conclusions 
of the article in any way.
The original article has been updated.
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